Ambery P - Search Results

1

Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.

Parker VER, Robertson D, Erazo-Tapia E, Havekes B, Phielix E, de Ligt M, Roumans KHM, Mevenkamp J, Sjoberg F, Schrauwen-Hinderling VB, Johansson E, Chang YT, Esterline R, Smith K, Wilkinson DJ, Hansen L, Johansson L, Ambery P, Jermutus L, Schrauwen P. Parker VER, et al. Among authors: ambery p. Nat Metab. 2023 Dec;5(12):2086-2093. doi: 10.1038/s42255-023-00938-0. Epub 2023 Dec 8. Nat Metab. 2023. PMID: 38066113 Free PMC article. Clinical Trial.

2

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.

Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B. Ambery PD, et al. Br J Clin Pharmacol. 2018 Oct;84(10):2325-2335. doi: 10.1111/bcp.13688. Epub 2018 Aug 7. Br J Clin Pharmacol. 2018. PMID: 29926478 Free PMC article. Clinical Trial.

3

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Ambery P, et al. Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. Lancet. 2018. PMID: 29945727 Clinical Trial.

4

Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status.

Berni E, Pritchard N, Jenkins-Jones S, Ambery P, Jain M, Jermutus L, Scott LA, Currie CJ. Berni E, et al. Among authors: ambery p. Endocrinol Diabetes Metab. 2018 Jul 8;1(4):e00029. doi: 10.1002/edm2.29. eCollection 2018 Oct. Endocrinol Diabetes Metab. 2018. PMID: 30815560 Free PMC article.

5

Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status.

Currie CJ, Berni ER, Berni TR, Jenkins-Jones S, Sinsakul M, Jermutus L, Ambery P, Jain M. Currie CJ, et al. Among authors: ambery p. PLoS One. 2019 Aug 28;14(8):e0221044. doi: 10.1371/journal.pone.0221044. eCollection 2019. PLoS One. 2019. PMID: 31461449 Free PMC article.

6

Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor.

Nyimanu D, Kuc RE, Williams TL, Bednarek M, Ambery P, Jermutus L, Maguire JJ, Davenport AP. Nyimanu D, et al. Among authors: ambery p. Peptides. 2019 Nov;121:170139. doi: 10.1016/j.peptides.2019.170139. Epub 2019 Aug 28. Peptides. 2019. PMID: 31472173 Free PMC article.

7

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.

Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B. Parker VER, et al. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz047. doi: 10.1210/clinem/dgz047. J Clin Endocrinol Metab. 2020. PMID: 31608926 Clinical Trial.

8

Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr¹]apelin-13 in humans.

Nyimanu D, Kay RG, Sulentic P, Kuc RE, Ambery P, Jermutus L, Reimann F, Gribble FM, Cheriyan J, Maguire JJ, Davenport AP. Nyimanu D, et al. Among authors: ambery p. Sci Rep. 2019 Dec 27;9(1):19934. doi: 10.1038/s41598-019-56157-9. Sci Rep. 2019. PMID: 31882594 Free PMC article.

9

Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes.

Edner NM, Heuts F, Thomas N, Wang CJ, Petersone L, Kenefeck R, Kogimtzis A, Ovcinnikovs V, Ross EM, Ntavli E, Elfaki Y, Eichmann M, Baptista R, Ambery P, Jermutus L, Peakman M, Rosenthal M, Walker LSK. Edner NM, et al. Among authors: ambery p. Nat Immunol. 2020 Oct;21(10):1244-1255. doi: 10.1038/s41590-020-0744-z. Epub 2020 Aug 3. Nat Immunol. 2020. PMID: 32747817 Free PMC article. Clinical Trial.

10

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.

Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Javaheri A, Ambery P, Gasparyan SB, Buenconsejo J, Sjöström CD, Langkilde AM, Oscarsson J, Esterline R. Kosiborod M, et al. Among authors: ambery p. Diabetes Obes Metab. 2021 Apr;23(4):886-896. doi: 10.1111/dom.14296. Epub 2021 Jan 19. Diabetes Obes Metab. 2021. PMID: 33319454 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page